Date: 2013-04-01
Type of information: Production agreement
Compound: Cetrotide® (cetrorelix acetate for injection)
Company: Aeterna Zentariis (Canada) Merck KGaA, Merck Serono (Germany)
Therapeutic area: Woman's health
Type agreement: manufacturing
production
Action mechanism:
Disease:
Details: * On April 17, 2013, Aeterna Zentaris has announced that its German subsidiary has transferred manufacturing rights and granted a manufacturing license for Cetrotide® to Merck Serono, in all jurisdictions. In addition, the Company has also entered into a transitional services agreement with Merck KGaA under which the Company will, during a 36-month period, provide various transition services to assist Merck KGaA in assuming responsibility for the manufacturing of Cetrotide® in consideration for the payment of a monthly fee to the Company throughout such period.
Cetrotide® (cetrorelix acetate for injection) is used to regulate hormone responses in women undergoing infertility treatment. Merck Serono, a leader in the field of fertility treatments, currently markets Cetrotide® worldwide, excluding Japan .
Financial terms: Subject to the satisfaction of customary closing conditions, the transaction is expected to be completed on or about October 1, 2013, at which time Aeterna Zentaris would receive a one-time payment of €2.5 million, or approximately $3.2 million and certain other payments.
Latest news:
